Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study

Purpose Apalutamide plus androgen-deprivation therapy (ADT) has been approved for treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) based on data from phase 3 TITAN study. This analysis was conducted to describe pharmacokinetics of apalutamide and N -desmethyl-apalut...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2022-05, Vol.89 (5), p.629-641
Hauptverfasser:	T’jollyn, Huybrecht, Ackaert, Oliver, Chien, Caly, Lopez-Gitlitz, Angela, McCarthy, Sharon, Ruixo, Carlos Perez, Karsh, Lawrence, Chi, Kim, Chowdhury, Simon, Ruixo, Juan-Jose Perez, Agarwal, Neeraj
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Androgen Antagonists - adverse effects Cancer Research Castration Coefficient of variation Deprivation Exanthema Exanthema - chemically induced Exposure Humans Male Medicine Medicine & Public Health Metastases Metastasis Oncology Original Article Patients Pharmacokinetics Pharmacology Pharmacology/Toxicology Placebos Prostate cancer Prostatic Neoplasms, Castration-Resistant Pruritus Pruritus - chemically induced Quartiles Regression analysis Skin Statistical analysis Survival Thiohydantoins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!